Advanced non-small cell lung cancer patients with low tumor mutation burden might derive benefit from anti-programmed cell death (PD) -1 and anti-programmed deathligand 1 (PD-L1) blockade
Nie, W.; Xu, M-D.; Gan, L.; Zhang, Y.; Han, B-H.
Annals of Oncology Official Journal of the European Society for Medical Oncology 30 Suppl. 2: Ii62
2019
ISSN/ISBN: 0923-7534 PMID: 32131310 DOI: 10.1093/annonc/mdz063.068
Accession: 069878630
PDF emailed within 0-6 h: $19.90
Related References
Rizvi, H.; Sanchez-Vega, F.; La, K.; Chatila, W.; Jonsson, P.; Halpenny, D.; Plodkowski, A.; Long, N.; Sauter, J.L.; Rekhtman, N.; Hollmann, T.; Schalper, K.A.; Gainor, J.F.; Shen, R.; Ni, A.; Arbour, K.C.; Merghoub, T.; Wolchok, J.; Snyder, A.; Chaft, J.E.; Kris, M.G.; Rudin, C.M.; Socci, N.D.; Berger, M.F.; Taylor, B.S.; Zehir, A.; Solit, D.B.; Arcila, M.E.; Ladanyi, M.; Riely, G.J.; Schultz, N.; Hellmann, M.D. 2018: Molecular Determinants of Response to Anti-Programmed Cell Death (PD)-1 and Anti-Programmed Death-Ligand 1 (PD-L1) Blockade in Patients With Non-Small-Cell Lung Cancer Profiled With Targeted Next-Generation Sequencing Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 36(7): 633-641Aso, M.; Toi, Y.; Sugisaka, J.; Aiba, T.; Kawana, S.; Saito, R.; Ogasawara, T.; Tsurumi, K.; Ono, K.; Shimizu, H.; Domeki, Y.; Terayama, K.; Kawashima, Y.; Nakamura, A.; Yamanda, S.; Kimura, Y.; Honda, Y.; Sugawara, S. 2019: Association Between Skin Reaction and Clinical Benefit in Patients Treated with Anti-Programmed Cell Death 1 Monotherapy for Advanced Non-Small Cell Lung Cancer oncologist 2019
Jove, M.; Vilariño, N.; Nadal, E. 2019: Impact of baseline steroids on efficacy of programmed cell death-1 (PD-1) and programmed death-ligand 1 (PD-L1) blockade in patients with advanced non-small cell lung cancer Translational Lung Cancer Research 8(Suppl. 4): S364-S368
Fouchard, M.; Jantzem, H.; Quere, G.; Descourt, R.; Robinet, G.; Poureau, P-Guillaume. 2019: Three cases of immune cholangitis related to anti-programmed cell death and programmed cell death ligand agents for the treatment of non-small cell lung cancer European Journal of Cancer 115: 107-110
Rivera, N.; Boada, A.; Bielsa, M.Isabel.; Fernández-Figueras, M.Teresa.; Carcereny, E.; Moran, M.Teresa.; Ferrándiz, C. 2017: Hair Repigmentation During Immunotherapy Treatment With an Anti-Programmed Cell Death 1 and Anti-Programmed Cell Death Ligand 1 Agent for Lung Cancer JAMA Dermatology 153(11): 1162-1165
Nie, W.; Xu, M.-D.; Gan, L.; Zhang, Y.; Qian, J.; Gu, K.; Zhang, X.-Y.; Wang, H.-M.; Yan, B.; Gu, P.; Zhang, B.; Wang, S.-Y.; Hu, F.; Li, C.-H.; Zhong, H.; Han, B.-H. 2020: Advanced Non-Small Cell Lung Cancer Patients with Low Tumor Mutation Burden Might Derive Benefit from Immunotherapy Journal of ImmunoTherapy 43(6): 189-195
Chen, J.; Chen, Y.; Feng, F.; Chen, C.; Zeng, H.; Wen, S.; Xu, X.; He, J.; Li, J. 2018: Programmed cell death protein-1/programmed death-ligand 1 blockade enhances the antitumor efficacy of adoptive cell therapy against non-small cell lung cancer Journal of Thoracic Disease 10(12): 6711-6721
Arbour, K.C.; Mezquita, L.; Long, N.; Rizvi, H.; Auclin, E.; Ni, A.; Martínez-Bernal, G.; Ferrara, R.; Lai, W.Victoria.; Hendriks, L.E.L.; Sabari, J.K.; Caramella, C.; Plodkowski, A.J.; Halpenny, D.; Chaft, J.E.; Planchard, D.; Riely, G.J.; Besse, B.; Hellmann, M.D. 2018: Impact of Baseline Steroids on Efficacy of Programmed Cell Death-1 and Programmed Death-Ligand 1 Blockade in Patients With Non-Small-Cell Lung Cancer Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 36(28): 2872-2878
Tan, D.S.W. 2017: Changing the Natural History of Non-Small-Cell Lung Cancer Through Upfront Programmed Death Protein 1/Programmed Death-Ligand 1 Blockade Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 35(24): 2735-2736
Ilie, M.; Juco, J.; Huang, L.; Hofman, V.; Khambata-Ford, S.; Hofman, P. 2018: Use of the 22C3 anti-programmed death-ligand 1 antibody to determine programmed death-ligand 1 expression in cytology samples obtained from non-small cell lung cancer patients Cancer Cytopathology 126(4): 264-274
Santoni, M.; Conti, A.; Buti, S.; Bersanelli, M.; Foghini, L.; Piva, F.; Giulietti, M.; Lusuardi, L.; Battelli, N. 2018: Risk of fatigue in cancer patients treated with anti programmed cell death-1/anti programmed cell death ligand-1 agents: a systematic review and meta-analysis ImmunoTherapy 10(15): 1303-1313
Ready, N.; Hellmann, M.D.; Awad, M.M.; Otterson, G.A.; Gutierrez, M.; Gainor, J.F.; Borghaei, H.; Jolivet, J.; Horn, L.; Mates, M.; Brahmer, J.; Rabinowitz, I.; Reddy, P.S.; Chesney, J.; Orcutt, J.; Spigel, D.R.; Reck, M.; O'Byrne, K.John.; Paz-Ares, L.; Hu, W.; Zerba, K.; Li, X.; Lestini, B.; Geese, W.J.; Szustakowski, J.D.; Green, G.; Chang, H.; Ramalingam, S.S. 2019: First-Line Nivolumab Plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer (CheckMate 568): Outcomes by Programmed Death Ligand 1 and Tumor Mutational Burden as Biomarkers Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 37(12): 992-1000
Iafolla, M.A.J.; Juergens, R.A. 2017: Update on Programmed Death-1 and Programmed Death-Ligand 1 Inhibition in the Treatment of Advanced or Metastatic Non-Small Cell Lung Cancer Frontiers in Oncology 7: 67
Zalcman, G.; Rizvi, N.A.; Lena, H.; Wolf, J.; Mazieres, J.; Antonia, S.J.; Minenza, E.; Planchard, D.; Lestini, B.J.; Ramalingam, S.S. 2015: 104Pd * Phase 2 Study Of Nivolumab (Anti-Programmed Death-1 [Pd-1]) In Patients (Pts) With Advanced, Refractory Squamous (Sq) Non-Small Cell Lung Cancer (Nsclc) Annals of Oncology 26(Suppl 1): i32-i33
Mattson, M.P.; Furukawa, K. 1997: Anti-apoptotic actions of cycloheximide: blockade of programmed cell death or induction of programmed cell life? Apoptosis: An International Journal on Programmed Cell Death 2(3): 257-264
Naqash, A.Rafeh.; Stroud, C.Robert.Geoffrey.; Butt, M.Umer.; Dy, G.K.; Hegde, A.; Muzaffar, M.; Yang, L.V.; Hafiz, M.; Cherry, C.R.; Walker, P.R. 2018: Co-relation of overall survival with peripheral blood-based inflammatory biomarkers in advanced stage non-small cell lung cancer treated with anti-programmed cell death-1 therapy: results from a single institutional database Acta Oncologica 57(6): 867-872
Kiriu, T.; Yamamoto, M.; Nagano, T.; Koyama, K.; Katsurada, M.; Tamura, D.; Nakata, K.; Tachihara, M.; Kobayashi, K.; Nishimura, Y. 2019: Prognostic Value of Red Blood Cell Distribution Width in Non-small Cell Lung Cancer Treated With Anti-programmed Cell Death-1 Antibody In Vivo 33(1): 213-220
Sun, X.; Roudi, R.; Dai, T.; Chen, S.; Fan, B.; Li, H.; Zhou, Y.; Zhou, M.; Zhu, B.; Yin, C.; Li, B.; Li, X. 2019: Immune-related adverse events associated with programmed cell death protein-1 and programmed cell death ligand 1 inhibitors for non-small cell lung cancer: a PRISMA systematic review and meta-analysis Bmc Cancer 19(1): 558
Gettinger, S.N.; Horn, L.; Gandhi, L.; Spigel, D.R.; Antonia, S.J.; Rizvi, N.A.; Powderly, J.D.; Heist, R.S.; Carvajal, R.D.; Jackman, D.M.; Sequist, L.V.; Smith, D.C.; Leming, P.; Carbone, D.P.; Pinder-Schenck, M.C.; Topalian, S.L.; Hodi, F.Stephen.; Sosman, J.A.; Sznol, M.; McDermott, D.F.; Pardoll, D.M.; Sankar, V.; Ahlers, C.M.; Salvati, M.; Wigginton, J.M.; Hellmann, M.D.; Kollia, G.D.; Gupta, A.K.; Brahmer, J.R. 2015: Overall Survival and Long-Term Safety of Nivolumab (Anti-Programmed Death 1 Antibody, BMS-936558, ONO-4538) in Patients With Previously Treated Advanced Non-Small-Cell Lung Cancer Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 33(18): 2004-2012
Zhao, C.Yunjia.; Consuegra, G.; Chou, S.; Fernández-Peñas, P. 2017: Intracorneal pustular drug eruption, a novel cutaneous adverse event in anti-programmed cell death-1 patients that highlights the effect of anti-programmed cell death-1 in neutrophils Melanoma research 27(6): 641-644